ArticleBMC cardiovascular disorders2026
Minimally invasive cardiac surgery - coronary artery bypass grafting in patients with low left ventricular ejection fraction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with coronary artery disease (CAD) with low left ventricular ejection fraction (LLVEF) (LVEF ≤ 35%) are not considered suitable for minimally invasive cardiac surgery - off-pump coronary artery bypass grafting (MICS OPCABG) due to poor cardiac function reserve.
methodsWe retrospectively analyzed 38 consecutive CAD patients with LLVEF who underwent MICS OPCABG from January 2022 to December 2024. We collected perioperative and follow-up data to evaluate the feasibility of this procedure as well as mid-term prognosis.
resultsThe mean age of the study patients was 65.5 ± 8.8 years, and the preoperative LVEF was 29.2 ± 4.0%. 15 patients (39.5%) had diabetes mellitus, 6 patients (15.8%) had chronic kidney disease (CKD). Mitral regurgitation (MR) was combined in 36 cases (94.7%). The in-hospital mortality rate was 7.89% (3/38). LVEF gradually improved: it increased to 42.3 ± 6.8% at postoperative 3 months (P < 0.001vs baseline), 48.1 ± 7.2% at postoperative 12 months (P < 0.001vs baseline), and stabilized at 49.5 ± 6.5% at postoperative 24 months. Mitral regurgitant area (MRA) was significantly reduced: it decreased to 5.1 ± 2.3 cm² at postoperative 3 months (P < 0.001vs baseline), and stabilized at 4.9 ± 2.3 cm² at postoperative 12 months (P < 0.001vs baseline), and 4.8 ± 2.1 cm² at postoperative 24 months. The 3-year all-cause cumulative mortality rate was 15.29%. Multivariable Cox regression showed that preoperative LVEF ≤ 25% (HR = 3.29, 95%CI 1.98–9.83, P = 0.022), combined preoperative CKD (HR = 2.77, 95%CI 1.08–6.65, P = 0.026) and LIMA-LAD blood flow ≤ 15 ml/min (HR = 1.97, 95%CI 1.31–3.93, P = 0.041) were independent predictors of 3-year mortality. In addition, the 3-year all-cause cumulative graft patency rate was 87.23%.
conclusionsMICS OPCABG provides a combined improvement in LVEF and MR and a favorable graft patency rate for CAD patients with LLVEF and ischemic MR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.